Oral presentation

European policy issues that affect OUD treatment access

10:50 to 11:05

Gabriele Fischer

Impact of chronic cannabis use on physical health

Hugo López-Pelayo

Injury and cannabis use: Intentional and unintentional lesions

Eugènia Campeny

Cerebellum and cannabis: research and clinical implications

Chrysanthi Blithikioti

Impact of cannabis use: integration of all research

Laia Miquel

10:55

Dynamics in emerging drug use prevalence among people who inject drugs in Ukraine between 2013 and 2017

Slava Kushakov

11:00

Lessons learned from 25 years of drug checking in the Netherlands

Blunted ventral striatal responses to anticipated rewards foreshadow problematic drug use in novelty-seeking adolescents

Views about the disease and brain disease model of addiction: an international survey of addiction treatment providers in the USA, UK and Australia

Anthony Barnett

Vital signs: the future of the harm reduction model in the National Health Service

Are we addressing alcohol-attributable deaths?

Francisco Goiana-da-Silva

Drug deaths in Scotland: inevitable or preventable?

Classification of behavioral addiction

ICHOM Standard Set development process

Digital phenotyping for the prevention of alcohol misuse

11:05

Overview of potential benefits of depot therapies, reviewing several newer buprenorphine depot formulations including the 6-month implants

11:05 to 11:30

Michelle Lofwall

11:10

Patterns of NPS consumption and perceived risks and benefits: results of online survey in Georgia

11:10 to 11:25

David Otiashvili

11:15

Harm reduction agencies and monitoring the responses to drug-related harm

Epigenetics of drug addiction: a therapeutic opportunity and a transgenerational inheritance concern

Reconsidering cannabis dependence

Liz Temple

Harm reduction and public health: the case of Sweden

The long-term impact of the Israeli national program to reduce alcohol problem drinking among children and youth: a nine-year follow-up 2010-2019

Yossi Harel-Fisch

Cause-specific excess mortality in people who use opioids illicitly: systematic review and meta-analysis

Methodological consideration in the study of behavioral addictions

Preliminary recommendations

Lessons from the gaming industry: a nurse’s perspective

11:25

Research on the use of new psychoactive substances and challenges in responding to it in Moldova (Eastern Europe)

11:25 to 11:40

Eliza Kurcevic

11:30

Monitoring drug use through wastewater analysis in Spain

An astrocyte-microglia crosstalk mediating neuroinflammation under exposure to psychostimulants

Agreement degree with the content of the Substance Addiction Consequences Scale items - The development of a new instrument.

Paulo Seabra

Harm reduction drug policy in Israel: what has and still needs to be accomplished?

Theoretical approaches of behavioral addictions

Digital treatment for substance use disorders: enhancing the therapist or are the machines taking over?

Open-label safety study conducted in Europe, Australia and the US

11:30 to 11:55

Genie Bailey

Prevention of drug related mortality: the role of opioid agonist treatment

11:30 to 12:00

Matthew HickmanLouisa Degenhardt

11:40

Drug use, HIV, HCV, including in prisons, in Eastern Europe: trends and implications for policy and programmes

Lyuba Azbel

11:45

ESCAPE (European Syringe Collection & Analysis Project Enterprise): a multi-city study of monitoring consumption trends of people who inject drugs

Acute psychotropic effects of 9-tetrahydrocannabinol (THC) associated with resting state brain function in the human insula: a pharmacological MRI study

Characterising people that demanded drug treatment in Catalonia: a cluster analysis

Xavier Majó

Street Support Project: a harm reduction approach to urban health and integration

Associations between negative life events and adolescent alcohol/drug-related problems, and the potential moderating role of individual and social resilience factors. The youth@hordaland-survey

Ove Heradstveit

Expert consensus on diagnostic criteria for assessing video gaming disorder: an international Delphi study

11:55

The implications for European patients, practice and policy

11:55 to 12:20

Gabriele FischerSharon L. Walsh

12:00

Synthetic cannabinoids 5F-PB22 and THJ-2201 promote neuronal differentiation in neureblastoma cells at biologically relevant concentrations

Discussant

13:20

The epidemiology of drug use and hepatitis C — Where are we now?

Epidemiology of drug-related deaths in Europe, and focus in two countries on underestimation and possible corrections of the reported number of deaths

Isabelle Giraudon

Comparison between drug-related deaths data from special and general mortality registers in Austria. Implications for monitoring and policy making

Judith Anzenberger

Mortality during and after opioid substitution treatment in Austria 2002 to 2016

Martin Busch

Prison post-release mortality among drug-users in Lithuania

Lina Jurgelaitiene

Social learning theory and the globalisation of drug demand reduction education programs

The systematic mapping survey of academic degree university programs focus on addiction science: up-dated overview

Understanding the nature of university-based addiction training programs: results of an international survey

The role of addiction education programs in the development of national strategies to address drug demand reduction

13:25

Alama-nightlife: Understanding the dynamics and consequences of young adult substance use pathways, a longitudinal and momentary analysis in the European nightlife scene

13:30

Speculating on the social effects of shifting drugs and addictions

ARBD: Systematised tools for the study of cognitive function in patients with alcohol dependence

A retrospective analysis of a turbulent decade for drug policy; 2009-2019

Danilo Ballotta

The advantages and challenges of developing a national earlier warning system - Transforming Bergen Earlier Warning System (BEWS) into Norwegian National Earlier Warning System (NNEWS).

Else Kristin Utne Berg

Substance Use Sex Index (SUSI): towards a new behaviour change assessment tool

Nadine Ezard

Models for the decriminalisation, depenalisation and diversion of illicit drug possession: an international realist review

Caitlin Hughes

Balancing welfare and market institutional logics. Procurement regulations for social services, such as addiction treatment, in four Nordic welfare countries

Kerstin Stenius

13:35

What future strategies will enhance integration of care for drug use and hepatitis C?

13:40

Understanding the interplay between cultural, biological and subjective factors in drug use pathways

13:45

How might the past and present shape the future? The case of 'drug control'

ARBD: Cognitive impairment produced by alcohol chronic consumption in alcohol dependent patients

New psychoactive substances in Portugal

Chemsex experiences: pleasures, harms and care

Maitena Milhet

To what extent will the drug-crime nexus remain after drug laws liberalisation? An examination of criminal charges among patients in treatment for cannabis use disorders and controls under varied drug policy regimes

Anne Line Bretteville-Jensen

Can liaison and diversion services increase referral to drug and alcohol treatment?

Kate Morley

Views, positions and objectives of Russia and like-minded countries

Anna Nazarova

13:50

How can modelling inform future interventions to integrate hepatitis C care and drug user health?

13:55

ATTUNE: Stimulant users in Europe - a state of the art project, reporting on findings and findings to expect

14:00

What kind of addiction treatments, and effects, will biotechnological developments make?

ARBD: Evolution and response to treatment based on cognitive variables

Views, positions and objectives of Mexico and like-minded countries to tackle the world drug problem

Diego Simancas

Recent use of synthetic cannabinoids, synthetic opioids and other psychoactive drug groups among high-risk drug users in Israel.

The counselors’ perspective on the use of methamphetamine in a sexual context among men who have sex with men

Valérie Aubut

The law enforcement costs of de facto 'criminalising' drug possession: the Italian experience

Davide Fortin

Treatment in therapeutic communities: the experience of Lisbon and Tagus Valley Region

Elizabete Pereira

14:05

What is the future role of policy makers to facilitate better integration of hepatitis C and drug user health?

14:05 to 14:20

Ricardo Baptista Leite

14:10

Sensory processing sensitivity and drug use recovery pathways

14:15

A viewpoint from civil society

Marie Nougier

Use of physiologically based pharmacokinetic modelling of new psychoactive substances

Faster, higher, stronger? Results from a Belgian survey on PED use among gym-goers

Bertrand Fincoeur

Introducing a new cannabis decriminalisation policy: The unintentional effects on cannabis perceptions and use among Israeli youth

Yossi Harel-Fisch

The influence of institutional response on the individual's recovery from drug misuse

Carolina Cunha

Digital and social media technologies: from drug markets and user networks to detection and surveillance

14:20

What is required for better integration of hepatitis C and drug user health in the future: a community perspective?

14:25

Pathways to addiction recovery: mechanisms of change in the UK, Belgium and the Netherlands

14:30

Combining monitoring data to evaluate responses to NPS: the case of 4-FA in the Netherlands

14:40

Illicit drug policies and social outcomes: a cross-country analysis

15:00

The EMCDDA 'Harm reduction initiative' to promote access to hepatitis testing and care

15:00 to 15:15

Klaudia Palczak

The contribution of injecting drug use as a risk factor for Hepatitis C virus transmission globally, regionally, and at country level: a modelling study

The current drug situation in the Central Asia

Viktor Mravčík

Results and lessons learned of prevention program to support parents (Closer each other-further from risky behaviours) implemented in Tajikistan and Kazakhstan

Janusz SieroslawskiBoguslawa Bukowska

The situation of harm reduction and treatment of drug use disorders in public health and in prison system in Central Asia

Ingo MichelsHeino Stöver

Opportunities for supporting modernisation of traditional drug policies in Central Asia

John-Peter Kools

Online gambling in Portugal: a new concern for the future?

Domingos Duran

Online Gambling in Sweden: A New Challenge?

Anders Hakansson

Relapse factors in seeking treatment gambling disorder individuals: An exploratory study

Pedro Hubert

Sports betting and gambling disorder: A new reality in Spain

Susana Jimenez-Murcia

Safe Injection Facilities Zurich - 30 years of experience

Janine Lanz

Implementation of a drug consumption room: conflict management - case analysis and success factors

Simon WeisFlorian Meyer

Security, Intervention, Prevention (SIP Zurich): conflicts of use in public spaces:

Mara Brügger

What is the patient perspective of VR?

ALCO-VR: effectiveness of a VR-based tool to elicit cue-induced craving and anxiety responses among AUD patients

ALCO-VR software demonstration

15:10

Measuring unmet demand for alcohol and other treatment: the application of an Australian population-based planning model

A peer-led integrated approach for co-existing mental and addictive disorders: a longitudinal qualitative study of the first UK dual diagnosis anonymous

Raffaella Margherita Milani

Recognising that behaviour is often automatic, contingent on environmental cues and with limited self-regulation: the potentials of environmental prevention

The evolving opioid overdose crisis and the rising role of methamphetamine

Christopher Jones

Guidelines AUD in Europe

Overview: analysis of societal trends in communication

Drugs policy and Human Rights: Recent trends, developments and challenges at the United Nations

15:15

A checklist to identify barriers to HCV testing and linkage to care in drug treatment settings – an important element of a diagnostic process

15:15 to 15:25

Ruth Zimmermann

Factors associated with HIV and hepatitis C in the context of routes of drug administration among problem drug users in Latvia, 2018

15:25

The Knowledge questionnaire for staff working with PWID: feedback from a pilot study among 150 health service workers

15:25 to 15:35

Nicola Singleton

The treatment demand indicator in Europe: A common monitoring tool across 30 countries and its value for treatment systems planning

m-Health among illicit drug users: effectiveness, differential indication, risks and negative effects and ongoing developments among guided and unguided interventions

Michael Schaub

Invalidating adolescents' pro-cannabis opinions: a new tactic of prevention

Examination of emerging adults with opioid use disorders

Holly Hills

New technologies in AUD treatment

Leveraging unsolicited data from online drug communities: the value for drug policy scholarship

Human and sustainable drug policies : the Pompidou Group of the Council of Europe

15:35

How HCV testing and care can be delivered through drug services: Evidence-base, case studies and 'real life' implementation experiences

15:35 to 15:55

Dagmar HedrichEberhard Schatz

15:40

Development of a needs-based planning model to estimate required capacity of a substance use treatment system: A Canadian model

Associations of ketamine use with mental health and substance use outcomes at 12 months follow-up in young Europeans

Meryem Grabski

IDART- a national study on targeted injury prevention

Benedicte Joergenrund

Recent non-fatal opioid overdose: the effects of health service utilisation, alcohol and other drug use and demographic factors

Penelope Hill

Precision medicine in AUD

Cryptomarkets: just criminal settings or a new frontier for Harm Reduction?

What does it mean to adopt a Human Rights approach to drug policy?

15:45

HCV care in an opiate substitution therapy program: assessment of infection, liver-related damage, and treatment rates.

15:55

Users of alcohol and other drugs residing in the Metropolitan Region of São Paulo: Basis for the planning of a treatment system

The acceptability of psychedelics as treatment options in psychiatry. Data from GDS2019

Adam Winstock

Results of the EPOPS project: adaptation, implementation and evaluation of a programme empowering parents organisations for alcohol prevention in Spain and Portugal

In utero opioid exposure and risk of infections in childhood: a multinational Nordic cohort study

Marte Handal

New thoughts on outcomes in AUD treatment

The rise of cyberpsychology: How changing communication methods have created new behavioural addictions

Promoting human rights in UN drug policy: a civil society perspective

Roundtable discussion: identifying barriers and facilitators to HCV testing and access to hepatitis treatment-experience from two European countries

15:55 to 16:30

Nadine BerndtRita Cardoso SeixasKarolina Zakrzewska

16:00

Slamming, drug injection in sexual contexts: increased HIV and HCV exposure for MSM points to a need for intersectional approaches to harm reduction

16:00 to 16:15

Insights zone 3 (I3)

Marie Jauffret-Roustide

16:10

The evolution of methods to estimate specialist alcohol treatment capacity and access in the United Kingdom

Effectiveness and cost-effectiveness of adjunctive personalised psychosocial intervention in treatment-resistant maintenance opioid agonist therapy: a pragmatic, open-label, randomised controlled trial

John Marsden

Adolescents in need - study of the origin and demands of adolescents and youngsters arriving at West Lisbon CRI indicated prevention locals

Reducing inappropriate use of prescription opioids in hospital patients

Erin Winstanley

Pain in AUD

16:15

Hepatitis C virus reinfection following antiviral treatment among people who inject drugs: a systematic review and meta-analysis

16:50

Drug use, drug related problems and responses among women in Europe: latest European data

Eleni Kalamara

Female-oriented medicosocial responses in French drug treatment facilities. Results from the Ad-femina survey

Carine Mutatayi

Violence and substance use among women

Florence MabileauOurania Botsi

Prevalence and patterns of NPS use in general and school European populations

Julian Vicente

NPS use in self-selected respondents of the population (EU web-survey)

Julian Vicente

Assessing patterns of use of new psychoactive substances (NPS) – the NPS Euronet project

Noelia Salgueiro-González

Drug trends at UK festivals and self-reported information and treatment needs by people who use NPS

Katy MacLeod

Understanding nicotine harm reduction in all its facets

Swedish snus as an alternative to smoking

E-cigarettes as an aid to smoking cessation

Nicotine harm reduction and youth uptake

17:00

Scarce information on substance use by migrants in Europe

Challenges of individual responsibility in (addicted) gambling: a philosophical analysis

Susanne Uusitalo

Socioeconomic status and parental education in vulnerability for substance use disorders

Sabrina Molinaro

Predictors of treatment allocation guesses in a randomised controlled trial testing double-blind injectable hydromorphone and diacetylmorphine for severe opioid use disorder

National continua of care for HIV and hepatitis C across Europe

Erika Duffell

Harm reduction in drug addiction with special emphasis on women

Introduction and short presentation on harm reduction monitoring

Useful public health policy models need big data - but they also need theory

17:15

Categorising, registering and monitoring client migration background in drug treatment demand and other registries: a European overview

The prevalence of problematic Internet use in Malta among young persons aged 13–16 years: a quantitative research study

Anna Maria Vella

People with lifelong disability and their experiences of pubs and clubs in Australia

Hannah Pitt

Illicit stimulant use in the context of daily injectable opioid agonist treatment: a grounded theory study with patients receiving treatment for severe opioid use disorder in Vancouver, Canada

Continuum of care for people who inject drugs

Thomas Seyler

New data support reduced alcohol consumption as harm reduction strategy in individuals with alcohol dependence

Introduction of methods developed for CSO monitoring

Pattern analysis of 661,565 drug overdose deaths in the USA, 1979 to 2017

17:30

'Better practice' – for migrants in drug aid institutions

Unique versus shared associations of substance use disorders and behavioural addictions with major depression: a commonality analysis in a large sample of young Swiss men

Simon Marmet

Hospitalisation of children after prenatal exposure to methamphetamine

Svetlana Skurtveit

The effect of entry and retention in opioid substitution therapy on contact with the criminal justice system among opioid dependent people

Continuum of care in the PWID population in Germany

Ruth Zimmermann

e-cigarettes as harm reduction in smokers, what is the evidence?

Focus on monitoring HCV, overdose prevention and new drug trends

TripApp: opening data and promoting citizen science through a mobile application

17:45

Migration and mental health – the perception of mental health issues and services among migrants

Psychobiological approach to pathological and problematic gambling and gaming: systematic literature review

Artemisa R. Dores

Veterans, substance use and trauma-informed care: analysis of veterans’ treatment needs in a multi-state sample of inmates

Michele Pich

Depot buprenorphine for opioid dependence in prisons in NSW, Australia

Continuum of care in the prison population

Fadi Meroueh

Discussant

18:00

Evaluation of the gambling disorder construct

Jabulanis Maphisa Maphisa

The association of traumatic experiences, perceived discrimination and affective symptoms with substance use among Russian and Kurdish migrants in Finland: a population-based study

Essi Salama

Slow release oral morphine versus methadone for the treatment of opioid use disorder: a systematic review and meta-analysis

Continuum of care among the prison and PWID population in Luxembourg

Nadine BerndtRita Cardoso Seixas

Public health, drug use and migration

18:30

Translating and transferring drug prevention interventions across contexts: Learning from the EPPIC project :‘Exchanging Prevention practices on Polydrug use among youth in Criminal justice systems’ (CJS)

18:30 to 18:45

Rachel Herring

Healthy recovery: results and reflections from a stepped wedge randomised controlled trial of a healthy lifestyle intervention within substance dependence treatment

USODROGAS.PT: Portugal's drug use: a web based survey

18:30 to 18:45

André Tadeu

Acceptability and willingness to use a mobile drug consumption room in Lisbon

18:45

Peer recovery specialists in the drug treatment court: impact on participant outcomes from a randomised controlled trial

18:45 to 19:00

Steven Belenko

Clearing the smoke: vaping cannabis among adolescents. Recent trends and implications

Partnering with persons in long-term recovery from substance use disorder: experiences from a collaborative research project

18:45 to 19:00

Henning Pettersen

Drug consumption rooms – from a conceptual framework to a basic institutionalised service. The experience of Germany

19:00

'My first 48 hours out': continuity of health and psychosocial care for drug users after release from prison in four European countries

19:00 to 19:15

Wouter Vanderplasschen

Tobacco harm reduction: key themes

Validation of the Routine Opioid Outcome Monitoring (ROOM) screening tool in patients prescribed opioids for chronic pain

19:00 to 19:15

Suzanne Nielsen

How to develop a common adherence of all the stakeholders when implementing a drug consumption room?

19:15

Coercion into addiction treatment and subsequent substance use patterns among people who use illicit drugs in Vancouver, Canada

19:15 to 19:30

Andreas Pilarinos

A systematic review and network meta-analysis of the safety and effectiveness of smoking cessation medicines and electronic cigarettes

Adoption of publication procedures to improve research integrity by alcohol and other drug journals

19:15 to 19:30

Dennis Gorman

Against political odds: the establishment of a drug consumption room in Belgium.

19:15 to 19:30

Freya Vander Laenen

Thursday, 24 October

09:10

Neurobiological changes predating and following cannabis use onset: findings from longitudinal neuroimaging studies

09:25

Transitions from use of cannabis to dependence, and comparisons with other substances

09:40

Triangulating the evidence: exploring causality in the link between cannabis and mental health

10:30

EU Health Programme funding for actions addressing alcohol and drugs & European Social Fund plus (Health strand) and Internal Security Fund overview

10:50

The Mosaic approach to post-marketing surveillance

10:50 to 11:00

Richard Dart

A consensus approach to opioid substitution treatment outcomes and how they are monitored

10:50 to 11:10

Lucas Wiessing

Addressing the Future: An International Focal Point for Drug Demand Reduction

Joanna Travis-Roberts

Building an international credentialing system for drug demand reduction professionals

Establishing and Supporting a consortium of universities to provide academic provision of drug demand reduction

A European training initiative to encourage the growth of an international prevention workforce

Introduction to the European ATTUNE study: overview of aim, objectives and design of the project

Uwe Verthein

Understanding different pathways of ATS use over time: results and conclusions from in-depth qualitative interviews in five European countries

Amy O’Donnell

Motives for and consequences from ATS use: findings from a multinational survey of ATS users and non-users

Nienke Liebregts

Associations between personality traits, sensation seeking, self-efficacy, resilience and patterns of ATS use

Magdalena RowickaMarcus-Sebastian Martens

Impact of critical life events on ATS use trajectories

Benjamin Petruzelka

Drug related interventions in European prisons: provision, available evidence, gaps

Evidence and evidence-based interventions for people with drug related problems in prison settings

Implementation of harm reduction interventions in prison: what are the challenges

The first therapeutic community in French prisons: review and prospects

Evidence and practice: what are the challenges that drug professionals working in prison have to face

The role of addictions in better understanding how the brain works

Brain stimulation in the treatment of cocaine use disorder

Translational neuroimaging in addiction – from circuit mapping to neurofeedback therapies

Global patterns of opioid use and dependence: population harms, interventions, and future action

Public health implications of legalising the production and sale of cannabis for medicinal and recreational use

Responding to growing global stimulant use: challenges and opportunities

The new psychoactive substance phenomenon: current and future challenges for drug surveillance, control, and public health responses

Discussion and the future

Louisa DegenhardtPam DasPaul GriffithsWayne HallMichael FarrellAmy Peacock

11:00

Prescription Drug Misuse in the U.K.

David Wood

Prevalence of injecting and non-injecting high-risk opioid use in Switzerland over more than two decades: understanding associations with opioid agonist treatment and needle and syringe programs

Psychiatric comorbidity and intimate partner violence among women who inject drugs in Europe: a cross-sectional study

Judit Tirado-Muñoz

Buying-shopping disorder

An interactive training session

Richard Stranz

11:10

Quality of life as a monitoring outcome measure for OST

11:10 to 11:15

Bernd Schulte

11:15

A routine-outcome-management tool to measure outcome of harm reduction

11:15 to 11:20

Mads Uffe Pedersen

Prescription drug misuse in Spain

Francina Fonseca

20 years of communication on drugs: What are the new challenges for a monitoring centre?

A gendered approach to women’s lived experiences of gambling harm: preliminary findings

Simone McCarthy

Work addiction

Experiences from the field

Joana Pires

11:20

Outreach and low threshold services for health care and drug addiction

11:20 to 11:25

Hugo Faria

11:25

Identifying client needs when using treatment monitoring data to inform and improve nursing practice

11:25 to 11:30

Catherine Comiskey

11:30

Prescription drug misuse in Germany

John Schwarz

Monitoring local drug trends – looking back at 17 years of 'Monitoring system drug trends' in Frankfurt, Germany

How can partners influence the gambling habits of their gambler spouse?

Melissa Cote

Hypersexuality — Compulsive sexual behaviours — Problematic pornography use

The researcher perspective

Perrine Roux

11:45

Prescription drug misuse in France and Italy

Janetta Iwanicki

Implementing treatment demand indicator in West Africa: challenges and lessons learnt

Methamphetamine use during pregnancy and weak evidence of adverse neonatal outcomes

Roman Gabrhelik

Compulsive hoarding

The importance of advocacy

Eberhard Schatz

12:00

An Australian clinical research priority setting study for substance use disorder due to methamphetamine and emerging drugs of concern

Exercise addiction: new developments

13:20

Review of evidence on the prevalence of current use of cognitive enhancers, the effects of their use on workers and on work, as well as an introduction to the implications for occupational safety and health (OSH)

The need for further evidence to support policy making and practical interventions

William CockburnAnnick Starren

Futures zone 2 (F2)

Challenges posed from a policy perspective and look into current strategies for reduction of work-related injuries and ill-health, caused by drug use at the workplace

Futures zone 2 (F2)

Marie-Claire Lambrechts

13:25

The use of performance enhancing drugs managed in the workplace

13:30

'A more accurate understanding of drug use': a critical analysis of wastewater analysis technology for drug policy

Kari Lancaster

Low THC cannabis products in the EU

Use of contingency management (positive reinforcement with financial incentives) to encourage abstinence from heroin (PRAISE): a UK cluster randomised trial

Nicola MetrebianTimothy Weaver

Does exposure to opioid substitution treatment in prison reduce the risk of death after release? A national prospective observational study in England

John Marsden

Principles and strategies for post-marketing surveillance of prescription drugs

Development of lower-risk gambling guidelines

Translating research into policy: is 'advocacy' a dirty word?

Alison Ritter

The off-prescription use of modafinil: an online survey of perceived risks and benefits

HepCATT (Hepatitis C Assessment to Treatment Trial) in primary care: a cluster RCT of whether a complex intervention based on risk prediction algorithm tool and education can increase testing and diagnosis of HCV in primary care

Constructing alcohol screening and counselling: the attitudes of social work professionals and their clients

Understanding opioid drugs and important drug interactions in opioid-related deaths

Graeme Henderson

13:45

Beyond the substances: a multi-criteria analysis of spread of drugs in Europe

Giuliano Resce

Low-THC cannabis: results of a survey among Swiss users

Opioid maintenance treatment (OMT) – not life-long for all women? 10 years follow-up after pregnancy - how many stop OMT and what are the results?

Gabrielle Welle-Strand

Results of mortality cohort study of problem drug users in Poland.

Janusz Sieroslawski

Better methods: Novel methods and analyses to better understand prescription drug misuse

Couple treatment of pathological gambling: variables associated with better efficacy

Fentanyl overdose: naloxone reversibility and reduced cross tolerance

Rob Hill

Addiction practitioners and drug policy reform

Kasia Malinowska-Sempruch

Prospective cohort to assess the impact of removing non-prescription codeine in Australia

Real-life effectiveness of direct-acting antiviral treatment among chronic hepatitis C infected opioid substituted patients in Germany

The who, what, where, when and why of adults’ drinking occasions and their association with acute alcohol-related harm: a systematic review

14:00

A smartphone app to assess alcohol consumption behaviours: development, validity, compliance and reactivity

Rob Hester

Creating the light cannabis market in the EU: the Italian consumer experience

A look at the dark side of addiction treatment: a profile of those who drop out

Prescription opioid misuse in Europe: Past, present, and future

Coping strategies and dysfunctional symptomatoly in pathological gamblers.

Individual vulnerability as core risk factor for gambling disorder: implications for public health and gambling policies

Gerhard Bühringer

Characteristics and problematic opioid use in people prescribed opioids for CNCP over four years: a prospective cohort study

Hepatitis C Virus (HCV) elimination and the opioid crisis: joint problems, joint solution – results of a pilot programme

Heroin overdose: experimental testing and measurement in the laboratory (preliminary findings)

Basak Tas

Before rock bottom? Disrupting 'valid denial' amongst harmful drinkers with continuum beliefs

Nasal naloxone for overdose prevention in Norway: results from the first four years

Desiree Eide

14:15

New and fully automated workflow for alcohol consumption and drugs of abuse monitoring from one single blood droplet

Marc Luginbühl

Methadone serum concentrations and influencing factors: a naturalistic observational study

Incidence and predictors of drug overdoses among a cohort of patients treated for substance use disorder

Birgitte Thylstrup

The future of prescription drug abuse beyond opioids: A U.K. perspective

Chronic obstructive pulmonary disease (COPD) among opioid dependent patients in substitution treatment. A diagnostic study

Philip Bruggmann

A qualitative study of gabapentin use and misuse: perspectives of substance abuse treatment professionals

Service Integration: accessing HCV treatment for homeless PWIDs/ex-PWIDs attending community OST

Determinants for the effectiveness of an Online Ambulatory Service for Internet Addicts (OASIS)

Drug use in rural and suburban environments: challenges in a progressive drug policy setting

Ludmila Carapinha

14:30

Is methadone treatment more effective for lower socio-economic status opiate users? Results from a case crossover study in Lazio

Antonella Camposeragna

MDMA-related deaths in Australia

Amanda Roxburgh

Analysis of the content of used injecting paraphernalia in the Sydney supervised injecting facility

Elodie Lefrançois

Application of a preliminary 'qualitative' leximetric approach via an example: anti-drug laws, policies and social outcomes in Italy since 2000.

Carla Rossi

The cost-effectiveness of an HCV outreach intervention for at risk populations in London

Reduction in the population prevalence of chronic HCV among people who inject drugs associated with major scale-up of direct-acting antiviral therapy in community drug services: real world data

15:00

Why are COIs still a current issue? Recent issues & Examples

15:05

Conflicts of interest and the emerging cannabis industry

15:10

How have policies for legal medical and recreational cannabis shaped the development of new cannabis products?

Medical use of cannabis – a review of the regulatory frameworks and challenges

Liesbeth Vandam

Bioinformatics approach to dual diagnosis: the Psygenet project

Epidemiology of drug-related deaths in Europe, new trends in opioid-related deaths

Growing up in a context of parental substance use: adult children's lived experiences on attachment and intergenerational transmition of trauma

Florien Meulewaeter

‘EMSS Nightlife survey’: design and snapshot of findings in 5 European countries

Meryem Grabski

The problematic usage of internet: An overview

Zsolt Demetrovics

Purity, adulteration and price of drugs bought on-line versus off-line in the Netherlands

Predictive analysis of alcohol consumption and stress through the psychosocial variables of emotional intelligence and resilience

Filipa Coelhoso

Using data to help people use drugs more safely: lessons and outputs from the Global Drugs Survey

15:15

Conflict of interest declarations and dilemmas for addiction journals

15:25

Changes in cannabis products during legal sales in Washington State

Recreational cannabis legalisation in the Americas – design considerations and possible futures

Beau Kilmer

Dual depression and Triptophan metabolites

Take-home naloxone programmes: history and perspectives

Sir John StrangSibella Hare Breidahl

Insights zone 3 (I3)

Examining the pathways for young people with drug and alcohol dependence following residential treatment: a data linkage study

Sally NathanSarita Bista

Methodological challenges: comparing different samples and sampling strategies

Jon Waldron

Psychobiological approach to pathological and problematic gambling

Artemisa R. DoresFernando Barbosa

Harmful alcohol use among acutely ill hospitalised medical patients

Saranda Kabashi

Safer nicotine delivery devices?

15:40

The International Cannabis Policy Study: comparing cannabis markets in Canada and US states with and without legal cannabis

CBD and other low-THC cannabis products, the latest health fad or serious drug policy challenge

Brendan Hughes

Depression, microbiota and alcohol use disorder: the gut connection

A national DRD policy and the role of take-home naloxone within it

The relationship between drugs and crime from the perspective of young people in contact with criminal justice systems. A qualitative, cross-national research.

Franca Beccaria

Ecological momentary assessment of substance use (consequences) among ecstasy users

Ruben van Beek

Problematic internet use in differently diagnosed psychiatric patients

Giuseppe Bersani

A descriptive analysis of the illicit supply of new psychoactive substances within and from China

Somewhere to be: the spatiality’s of alcohol abuse and recovery in a non-interventionist, peer led centre.

Kirstie Soar

Safer Cannabis: a plant containing more than one hundred active compounds

Three primary principles in making decisions on relationships with funders and organisations with vested interests

15:55

Changes in European cannabis resin: new evidence from THC and THC/CBD ratios in Denmark

Kristine Rømer Thomsen

Mobilising evidence-based secondary prevention for cannabis use in legalisation contexts: The Lower-Risk Cannabis Use Guidelines (LRCUG)

Wayne Hall

Alcohol acceleration of cognitive impairment in preclinical models

Marta Rodriguez-Arias

Fentanyl overdose deaths emergency and response in Estonia

Substance use among college students in the Netherlands: a closer look at the prevalence of use and risk perception

Arne van den Bos

Contextual analysis and comparison of nightlife cultures in five European countries

Tina Van Havere

Cognitive findings in problematic usage of the internet

Konstantinos Ioannidis

MDMA dosage in XTC tablets: size matters

Sex and drugs can take their toll: understanding chemsex

16:10

Exploring comorbidities in addiction

16:10 to 16:20

Fernando Rodriguez de Fonseca

Health effects of new cannabis products in Europe

Key lessons for cannabis policy for the next decade

Michael Farrell

Reducing drug-related deaths in Europe: a systemic perspective with focus on take-home naloxone

Unfolding social and material practices of drug treatment for youth in Azerbaijan and Germany

Aysel Sultan

Insight into the reliability of self-report of substance use in nightlife populations: a breath sampling study

Kristin Feltmann

PIU and novel forms of substance misuse: a controversial relation

Pierluigi SimonatoAttilio Negri

Understanding drug markets: results of the MARSTUP study

16:50

A three-country study of pathways to recovery from problematic drug use: Background and overview

16:50 to 17:05

David Best

A community-based peer-driven program to reach people who inject drugs, monitor risk behaviours and 'test and treat' for infectious diseases in Athens, Greece: ARISTOTLE HCV-HIV

Modeling economical costs of alcohol consumption in Germany: the GECO-ALC1 project

16:50 to 17:05

Jakob Manthey

Monitoring systems

Insights zone 1 (I1)

Mimmi Erikkson Tinghög

National and regional coordination and initiative to achieve the objectives of the strategy

Assessing results of the ANDT strategy

17:00

First results from the EU-funded project NPS-PRISON

The European Drug Emergencies Network Plus (Euro-DEN Plus) project: what has it shown us over the last 5 years?

Which internalising disorders associate with harmful alcohol use in late adolescence and early adulthood?

Interpreting wastewater data alongside other population-level indicators of stimulant use

Hayley Jones

The impact of cannabis policy changes on cannabis use among adolescents: evidence from Europe

Elisa Benedetti

'I shouldn’t have taken that bet!': counterfactual thinking in gambling disorder

Luke Clark

Informal social support as a crucial factor in recovery from drug misuse

Alcohol policy in the Netherlands: the National Prevention Agreement

Dike van de Mheen

Cannabis use among people entering drug treatment. A growing phenomenon?

Framing the non-medical use of tramadol in Africa- global opioid crises, medicrime or inadequate healthcare systems

17:05

Uptake of testing, linkage to care, and treatment for hepatitis C infection among people who inject drugs in Australia: the ETHOS Engage Study

Estimating substance use costs and harms in Canada

17:05 to 17:20

Matthew Young

'It’s getting better all the time': Stable recovery and its relation to housing problems, crime, occupation situation, and substance use

17:05 to 17:25

Gera Nagelhout

17:15

Decriminalisation and possible impact on prison population and drug related problems

Prescription medicine misuse and related acute toxicity

Is the relationship between use of high potency cannabis and mental health explained by frequency of cannabis use?

What are the indirect causes of death among people who use drugs in Ireland? Findings from a comprehensive special register on drug related deaths

Suzi Lyons

Early evidence of the impact of cannabis legalisation on cannabis use, dependence and the use of other substances: a cautionary tale from the US

Rosalie Pacula

Income-related inequality in gambling: evidence from Italy

Giuliano Resce

Social and professional integration, addictive behaviours and time perspectives: personal experiences of young adults involved in a low-threshold employment program in Montreal

Portuguese alcohol and health forum experience as an ecological approach to the alcohol related harms

Alexandra Pinto

Comparing adolescent and adult vulnerability to cannabis use problems

17:20

Captagon: knowns and unknows

Low HCV-RNA prevalence and low anti HCV incidence in a large national sample of PWID in opioid substitution treatment in Germany: a prospective cohort study

Morbi-mortality consequences of misuse of psychoactive prescription drugs in Portugal: a retrospective observational study - the MisuMedPT project

17:20 to 17:35

Ana Araújo

17:25

Understanding recovery pathways: how different systems of treatment and support relate to meaningful participation in society

17:25 to 17:45

Thomas Martinell

17:30

Challenges and opportunities for drug related interventions in prison. An insider perspective

Comparison of the acute harms of the synthetic cannabinoids and cannabis

Patterns of cigarette and cannabis use across adolescence and later cognition and emotional processing: improving causal inference

Temporary and constant remission: a record-linkage study of a national cohort of people with psychoactive drug use disorders

Morten Hesse

In between recreational and medical cannabis supply models: is the Cannabis social club a potential buffer against market distortions?

Davide Fortin

Socio-ecological model of problem gambling: a cross-national comparison on young people in the United States, South Korea, Spain and Finland

Atte Oksanen

General practice patients in treatment for substance use problems at different levels of care: an observational study using two data sources

'Suspending your licence to drink': insights from an innovative criminal justice program

Beau Kilmer

Cannabis and tobacco co-use: implications for addiction

17:35

Libya’s changing drug trafficking dynamics on the coastal and desert borders

Monitoring the elimination of hepatitis C and B among people who inject drugs in Europe

17:45

Photovoice: an innovative method for participatory recovery research

17:45 to 17:55

Jessica De Maeyer

Women and vulnerable groups in prison: what are their drug problems and what are their needs?

Clinical coding of acute drug and NPS presentations: why doesn’t it work and what can be done

Subclinical alcohol related liver disease in young people – below the surface

Effective policies to support autonomous attempts to quit opioid use - a cross-sectional study across 14 countries

Larissa Maier

Online poker : loss of control and gambling disorder

Axelle Moreau

The Healthy Addiction Treatment (HAT) recovery model for addiction nursing services

The illicit cannabis market in Canada and US: findings from the International Cannabis Policy Study

Elle Wadsworth

Managers’ alcohol policy knowledge and inclination towards early alcohol interventions in the workplace: associations with sociodemographic, work-related and health characteristics

Devy Elling

Advances in the neurobiology of cannabis use disorders

17:50

Harm reduction services in MENA region: Assessment of the situation and response by MENAHRA

'Towards eliminating viral hepatitis': A critical examination of the performativity of hepatitis C elimination goals and targets

17:55

Recovery and national drug policies: discourse versus actual practice

17:55 to 18:05

Lore Bellaert

18:00

Marketing stimuli and their perceived effects among sports bettors in treatment for gambling disorder

Hibai Lopez-Gonzalez

'Once a drug addict, always a drug addict': the role of stigma in recovery

Cannabidiol: a novel treatment for cannabis cessation?

Alcohol intoxication management services in the night-time economy are highly acceptable to their users but they may not reduce demand on emergency services: a mixed methods study.

Simon Moore

18:05

Wastewater-based drug epidemiology data in selected community compared to a forensic toxicology investigation finding. Sewage sensors towards evaluation of drug use trends

Evidencing viral elimination futures: modelling, targets and the end of Hep C

18:30

Re-emergence of injecting drug use-related HIV despite a comprehensive harm reduction environment

Prevalence and characteristics of EC use in England

Effect of EC use for smokers with mental health problems

EC use in pregnancy

EC policy in England in comparison with other countries

Babel and Bleak House; what ELDD can and can’t tell us about drug laws in 30 countries

18:30 to 19:30

Brendan Hughes

tba

18:30 to 19:30

Scott Burris

Alison RitterPaul Griffiths

Discussants

18:30 to 19:30

Futures zone 1 (F1)

New HCV prevention strategies and tools: lessons learnt

18:30 to 19:50

Eberhard SchatzGabi Becker

18:40

Use of an adapted version of the community readiness assessment to examine the current state of alcohol prevention in communities in Spain and Portugal

18:40 to 18:55

Claudia Pischke

Cannabis labelling and consumer understanding of THC levels and serving sizes.

Modelling the effects and potentials of fentanyl and linked drug policy responses

18:45

Amphetamine-type stimulant use: global and European trends in the harm reduction response

18:50

HCV prevention — moderated exchange

18:50 to 19:10

Christine Rolle

18:55

Building systems to promote prevention science: challenges and strategies

18:55 to 19:10

Peer van der Kreeft

The impact of cannabis health warning labels on risk awareness and behaviour

Epidemiological futures: the study of addiction and the evaluation of addiction interventions

19:00

Implementation of an educational intervention for safer injection in the European context: preliminary results from the EUROSIDER project

19:10

Short presentation of developed materials and training curricula of Integrative Drogenhilfe

19:10 to 19:20

Christine Rolle

Minimum quality standards in drug demand reduction - from policy consensus to assessment and implementation

19:10 to 19:25

Matej Košir

The efficacy of health warnings and package branding on perceptions of cannabis products among youth and young adults.

A call for primary data collection to quantify drug-related harms

19:20

HCV prevention — moderated discussion

19:20 to 19:30

Gabi Becker

Friday, 25 October

09:00

What is the current evidence for the effectiveness of cognitive bias modification in addiction? A review, recent and large RCT and Bayesian meta-analysis

Effects of Attention-Control Training on detoxified drug abusers' attentional bias and other treatment indices

Attentional Bias Modification Training as add-on to regular treatment in alcohol and cannabis use disorder

tba

09:00 to 10:30

Susana Jimenez-Murcia

09:10

A framework for understanding the EU illicit drug market

Are 4 sessions of MET just as effective as 4+8 sessions of MET+CRA-S?

09:10 to 09:25

Kjeld Andersen

Presence and practices of cannabis social clubs within the European Union

09:10 to 09:25

Mafalda Pardal

09:15

Assessing the impact of laws controlling the online availability of 25I-NBOMe, AH-7921, MDPV and MXE – outcomes of a semi-automated e-shop monitoring. Drugs: education, prevention and policy

09:15 to 09:30

Vendula Belackova

09:25

Ramifications of illicit drug markets: pilot data on drug-related homicide

Does AUD-severity and age of onset predict outcome of treatment?

09:25 to 09:40

Silke Behrendt

Initial lessons and next steps for a public health approach to cannabis regulation in Canada

09:25 to 09:40

Rebecca Jesseman

09:30

Some constitutional issues regarding control of new psychoactive substances

09:30 to 09:45

Krzysztof Krajewski

09:40

3. Does the Alcohol Dependence Scale work in treatment-seeking older adults with DSM-5 AUD?

09:40 to 09:55

Anna Mejldal

Implementing cannabis regulation to achieve public health and safety goals in California – assessing the successes and challenges of the first year of regulation

09:40 to 09:55

Jennifer Price

09:45

Making the National Strategy on Addiction work for practitioners in addiction aid: how Swiss authorities and civil society bridge theory and practice

09:45 to 10:00

Mirjam Weber

09:55

The European markets for cannabis, heroin and cocaine

What do the elderly want of treatment?

09:55 to 10:10

Randi Bilberg

Development of new measures of cannabis market exposure: a case study in Colorado

09:55 to 10:10

Rosalie Pacula

10:00

Leveraging citizen science and the power of civil society networks in a trans European mobile application

10:00 to 10:15

Florian Scheibein

10:10

The European markets for synthetic stimulants and new psychoactive substances

Does fidelity to MI matter?

10:10 to 10:25

Lotte Kramer Schmidt

10:45

Development and contribution to software to monitor online discussions on internet drug discussion forums

Routine internet forum monitoring for new psychoactive substances: implementation of the EC funded I-TREND project results

Automated monitoring of online shops offering new psychoactive substances in the EU

Martin PazitnyVendula Belackova

Futures zone 1 (F1)

4-Fluoramphetamine in the Netherlands: Text-mining and sentiment analysis of internet drug discussion forums

Food addiction and impaired executive functions in women with obesity

Fernando Fernandez-Aranda

Neural correlates of cue-reactivity and craving in individuals with buying-shopping disorder.

Patrick Trotzke

Are the practices of 'free-to-play' and 'pay-to-win' games new risk behaviours?

Jean-Michel Costes

‘Hooked on the mirror’: the emergence of a new cohort of gym users affected by exercise addiction, appearance anxiety and the use of fitness supplements

Ornella Corazza

The importance of a therapeutic contract in a CBT gambling disorder treatment

Bruno Ricardo Neto Teixeira Bento

The role of substance use in intimate partner abuse perpetration: rationale forthe ADVANCE programme of research

Gail Gilchrist

The dynamics of intimate partner abuse and drug and alcohol dependency: results from qualitative dyad interviews with male perpetrators of intimate partner abuse perpetration in substance use treatment and their current or ex female partners

Juliet Henderson

Development of an integrated intervention to reduce intimate partner abuse perpetration by men in substance use treatment: the ADVANCE intervention

Gail Gilchrist

Assessing the feasibility of conducting an evaluation trial of the ADVANCE integrated intervention to address both substance use and intimate partner abuse perpetration to men in substance use treatment

Gemma Halliwell

Young people's addictions treatment

Deborah JudgeLisa Mellen

10:50

Reitox: the European information network on drugs and drug addiction

10:55

Investigating cognitive function among people with chronic non-cancer pain prescribed opioids: a longitudinal study

10:55 to 11:05

Jane Akhurst

Memory-focused cognitive therapy for cocaine use disorder: theory, procedures and preliminary evidence from an external pilot randomised controlled trial

John Marsden

Overdose deaths in people prescribed opioids for chronic non-cancer pain: Systematic review and meta-analysis

Evaluations of recreational cannabis legalisation in the US – overview and key lessons for policymakers

Beau Kilmer

Infectious diseases among people who inject drugs in France: the importance of acting on risk environment in an evolving crisis

Marie Jauffret-Roustide

Systematic review of untreated remission from alcohol problems: estimation lies in the eye of the beholder

11:00

Case study from Ireland: Use of data in public debate on alternative approaches to the possession of drugs for person use

11:05

Additional prescription of benzodiazepines, z-drugs and gabapentoids and mortality risk in people with opioid use disorder receiving opioid substitution therapy in primary care: prospective observational study using linkage between the CPRD and ONS death

11:05 to 11:15

Matthew Hickman

11:10

Treatment of youth with substance use disorder and co-existing mental disorder: the MOVE programme.

11:10 to 11:25

Mads Uffe Pedersen

Hidden aspects of the opioid crisis: what factors are driving ageing trends among those using opioid drugs?

Legalising cannabis for recreational purposes in Canada – practical challenges and opportunities for evaluating implementation and outcomes

11:10 to 11:25

Rebecca Jesseman

Pakistan’s heterogeneous HIV epidemic in people who inject drugs: identifying key contributing factors

Assertive outreach for high-need, high-cost alcohol related frequent NHS hospital attenders: characteristics of participants in an RCT of assertive outreach treatment

11:15

Non-medical drug use among prescription drug users

11:15 to 11:25

Karoliina Karjalainen

Case study from Czech Republic: role of evidence in drug (de)criminalisation in the Czech Republic

11:25

Buprenorphine-Naloxone abuse among participants in a needle exchange programme. A Finnish time-trend study from 2008 to 2018

11:25 to 11:35

Solja Niemelä

The impact of maternal alexithymia on parenting behaviours in the context of substance use disorders

11:25 to 11:40

Alessio Porreca

Comparing rates and characteristics of harms across different pharmaceutical opioids: an examination of Australian ambulance attendances 2013-2018.

The role of evaluation in the development of the EU approach on drugs

11:25 to 11:40

Danilo Ballotta

Modelling HIV transmission amongst high-risk groups to determine the extent that HIV transmission is driven by key populations and risk behaviours in Tijuana, Mexico

Applications of virtual reality and eye-tracking technologies in substance use disorders: the ALCO-VR project

11:30

Case study from France: Use of data in public debate on alternative approaches to the possession of drugs for person use

11:40

The role of social environment in pathways to recovery: a scoping review

João Pedro Ramos

Causes of death among patients in opioid maintenance treatment in Norway

Developing a flexible support package for EU Member States: EMCDDA’s ‘realistic’ policy evaluation approach

Nicola Singleton

Characteristics of polydrug use and associations with HIV risk behaviours among people who inject drugs in two cities in Europe

Isabel Tavitian-Exley

11:45

Decision-making and the use of evidence

11:55

Increased risk of HIV and other drug-related harms associated with injecting in public places: national bio-behavioural survey of people who inject drugs

Modelling the impact of prevention and treatment interventions on HIV and Hepatitis C virus transmission among PWID in Nairobi

11:55 to 12:10